生物制造
金丝桃素
代谢工程
基质(水族馆)
聚酮
化学
焊剂(冶金)
异源的
生物化学
天然产物
紫檀
生物
异源表达
候选药物
酶
中间代谢
生物反应器
药品
生物制药
烟草
组合化学
药物发现
合成生物学
底物特异性
通量平衡分析
生物合成
白藜芦醇
代谢途径
新陈代谢
作者
Qing Juan Cui,Xin Shi,Jia Hui Li,Yi Tong Shi,Hao Lan Chen,Xue Wu,Ren Xiang Tan
摘要
Abstract Hypericin is a promising Phase II/III drug candidate for oncology and psoriasis, yet its sustainable supply is problematic: multi-step synthesis is resource-intensive, and heterologous expression is blocked by the unknown plant pathway. Here, we re-engineer the polyketide biosynthetic pathways in Cladosporium fulvum and overcome substrate inhibition and metabolic inefficiency, achieving scalable and plant-pathway-independent biomanufacturing of hypericin. In particular, we redesigned the catalytic cavity of the critical P450 enzyme RugG to yield a variant (RugGT452P-R160D) with enhanced activity and reduced substrate inhibition. This achievement was combined with the suppression of shunt product formation to redirect metabolic flux toward emodin bianthrone—an indispensable hypericin precursor. These efforts enabled us to construct an engineered strain, ΔclaC-ΔclaH2-rugGT452P-R160D-claA-claE, which produced 1.87 g/L hypericin in a 5-L bioreactor after photocatalytic treatment. Collectively, this work provides an effective strategy for alleviating substrate inhibition and redirecting metabolic flux in the biomanufacturing of complex, high-value natural products.
科研通智能强力驱动
Strongly Powered by AbleSci AI